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Abstract
Genetically modified mice have played an important part in elucidating gene function in vivo. However, conclusions from
transgenic studies may be compromised by complications arising from the site of transgene integration into the genome
and, in inducible systems, the non-innocuous nature of inducer molecules. The aim of the present study was to use the
vascular system to validate a technique based on the bacterial lac operon system, in which transgene expression can be
repressed and de-repressed by an innocuous lactose analogue, IPTG. We have modified an endothelium specific promoter
(TIE2) with synthetic LacO sequences and made transgenic mouse lines with this modified promoter driving expression of
mutant forms of connexin40 and an independently translated reporter, EGFP. We show that tissue specificity of this
modified promoter is retained in the vasculature of transgenic mice in spite of the presence of LacO sequences, and that
transgene expression is uniform throughout the endothelium of a range of adult systemic and cerebral arteries and
arterioles. Moreover, transgene expression can be consistently down-regulated by crossing the transgenic mice with mice
expressing an inhibitor protein LacIR, and in one transgenic line, transgene expression could be de-repressed rapidly by the
innocuous inducer, IPTG. We conclude that the modified bacterial lac operon system can be used successfully to validate
transgenic phenotypes through a simple breeding schedule with mice homozygous for the LacIR protein.
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Introduction
For several decades, genetically modified mice have been the
premium tool for the study of gene function in vivo. However,
interpretation of the specific role of candidate genes can often be
compromised in transgenic studies by the random nature of the
site of transgene insertion into the host DNA [1,2]. This non-
specific ‘‘position effect’’ can result from transcriptional regulation
imposed on the transgene by the adjacent host sequences, or
alternatively, from the loss of function of genes which are
accidentally interrupted by insertion of the transgene [1,2].
Attempts to overcome these problems have employed inducible
systems, such as the Cre-LoxP or Doxycycline-controlled methods,
in which expression of the transgene can be regulated at specific
times by an inducer molecule. Thus, phenotypes due to the
transgene are isolated from effects due simply to the site of genetic
insertion (for reviews see [3,4]). However, both of these systems
employ non-innocuous inducers for the switching of gene
expression. The inducible CreERT system requires tamoxifen
and the Doxycycline system utilises the antibiotic tetracycline,
both of which can have off-target effects (reviewed in [4]).
Tamoxifen, in particular, as a selective modulator of both
membrane bound and intracellular estrogen receptors, is capable
of altering vascular tone and blood pressure [5]; effects which are
not conducive with uncovering a role for specific genes in
cardiovascular function.
With the intention of creating an alternative system which
utilises an innocuous inducer, Scrable and colleagues have
modified the bacterial lac operator system for use in mammalian
systems and reported reversible control of the tyrosinase gene and
eye pigmentation, as well as the Huntington promoter driving a
luciferase reporter, using the lactose analogue, Isopropyl b-D-1-
thiogalactopyranoside (IPTG) [6–8]. Their system relied on the
introduction into the tyrosinase and Huntington promoters of Lac
operon (LacO) sequences at specific distances spanning the
transcription start site (see also [3]); a procedure which did not
interfere with promoter function and specificity. However, in the
presence of the LacI repressor protein (LacIR), the function of the
promoter was repressed due to the binding of the LacIR protein to
the LacO sequences thereby blocking transcription. Following
addition of IPTG, the LacIR protein was modified by the IPTG to
undergo a conformational change that weakened its ability to bind
to the LacO sequences, thus permitting transcription factors to
again bind normally and reinstate transcription. In this manner,
gene function was controlled in a reversible manner using an agent
that had no deleterious effect even after 8 months of continuous
administration [6]. Surprisingly, only one report has appeared in
the intervening decade, and this investigation, which utilised the
haematopoietic system, failed to confirm that the LacIR/LacO
system could tightly and reversibly control gene expression [9].
However, results of this study were complicated by mosaic
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transgene expression amongst littermates within the same trans-
genic line [9]; effects likely due to the use of F2 progeny, in which
multiple transgene insertion sites still existed. Furthermore,
experiments in which IPTG was unable to reinstate transgene
expression in vivo employed only a single bolus exposure to IPTG
[9].
In the present study, we have re-evaluated the LacIR/LacO
system in the vasculature using transgenic mouse strains in which
transgene inheritance had stabilised. Our gene of interest was the
endothelial gap junctional protein, connexin40 (Cx40), for which
identification of a role in the control of vascular function and
blood pressure has been complicated by co-ordinate regulation of
other connexin family members (e.g. [10]). We have created
transgenic mouse lines that express mutant forms of Cx40 and an
independently translated reporter, EGFP, selectively in the
endothelium, through use of the endothelial specific promoter
TIE2 and its enhancer [11].
We show that addition of LacO sequences to the TIE2 promoter
does not interfere with uniform transgene expression in the
endothelium of a range of adult systemic and cerebral arteries and
arterioles and that repression of promoter activity occurs reliably
in the presence of LacIR, although the capacity for re-activation by
daily administration of IPTG appears to vary with transgenic line.
Nevertheless, the robust tissue-specific expression of transgenes
directed by promoters modified with LacO sequences, combined
with the ability to significantly repress transgene function through
breeding to mice ubiquitously expressing LacIR, makes this an
attractive system to validate vascular phenotypes, ruling out
‘‘position effects’’ due to random transgene insertion.
Materials and Methods
Ethics Statement
All experimental animal procedures were carried out in strict
accordance with the recommendations in the Australian code of
practice for the care and use of animals for scientific purposes of
the National Health and Medical Research Council of Australia.
Protocols were approved by the Animal Experimentation Ethics
Committee of the Australian National University (JMB.33.07;
A2011/72).
Generation of TIE2LacO-Cx40-EGFP Constructs
Constructs were created in which Cx40 and Enhanced Green
Fluorescent Protein (EGFP) could be expressed separately through
the use of an internal ribosome entry site (IRES) which allows the
expression of a bicistronic mRNA and production of two
independent proteins from the same promoter. This construct
was coupled to the endothelial specific promoter, TIE2, as
described below. The transgenic constructs were composed, in
59 to 39 order, of a modified TIE2 promoter, the coding region of
Cx40 with single base mutation, an internal ribosomal entry
sequence (IRES), EGFP, human growth hormone poly A tail and
a TIE2 enhancer fragment (Figure 1A). Two different single base
mutations encoding amino acids at positions 152 (T152A) and 202
(T202S; [12]) were incorporated into separate constructs.
LacO sites were introduced into the TIE2 promoter to enable
regulation of transgene expression. The TIE2 enhancer fragment
was necessary for endothelial expression of the TIE2 promoter
throughout embryogenesis and adulthood [11].
TIE2LacO construct. The plasmid pHHSDKXK [11],
containing the TIE2 promoter and a minimal enhancer fragment,
as well as the plasmid pg50–2.11 containing the full length TIE2
enhancer, were generous gifts from Professor Tom Sato, The
University of Texas, Southwestern Medical Center at Dallas,
Texas, USA. A 2 kb TIE2 promoter fragment was recovered from
pHHSDKXK by Hind III digestion. This was inserted into
pBluescript KS II (pBKSII) by restricting with Hind III and Bam
HI, ligating the insert to the vector Hind III site, blunting the
vector BamH I and the fragment Hind III sites, and religating
(with loss of the BamH I restriction site) to give pBKSIITIE2. The
correct orientation of the TIE2 promoter was determined by
sequencing.
A BamH I – Nae I fragment was removed from this plasmid and
replaced with a synthetic fragment of the TIE2 promoter now
containing LacO sites. This synthetic BamH I-Nae I LacO
fragment, pUC57TIE2LacO (synthesised by Genscript, USA)
was designed with three 18 bp LacO sites (59-ATT-GTG-AGC-
GCT-CAC-AAT-39), that were introduced to span the transcrip-
tion start site, with 92 bp intervals, at positions –117,225 and +67
of the TIE2 promoter. These locations were determined not to
contain known transcription factor binding sites (MatInspector).
The resulting construct, TIE2LacO, contained the full length TIE2
promoter with 3 LacO sites.
TIE2LacO-Cx40-EGFP construct. Digestion of TIE2LacO
with Cla I, followed by blunting of the Cla I site, and partial
digestion with Bcl I allowed recovery of the 2.2 kb TIE2LacO
fragment. This was ligated into the Sac II digested, blunted, then
BamH I-digested 7.7 kb backbone fragment of pBKSII containing
the Cx40-IRES-EGFP construct.
The TIE2LacO-Cx40-EGFP plasmid was linearised by digestion
with Xho I, blunted, and ligated to the 10 kb TIE2 enhancer
fragment from Nae I and Sal I-digestion of pg50–2.11. The final
construct contained the enhancer in the forward orientation after
the polyadenylation signal (Figure 1A). Sequencing was performed
at each step to confirm the presence, fidelity, and orientation of
construct components.
Figure 1. Control of transgene function by the LacO/LacIR
system. (A) Construct used to create Cx40 transgenic mice consists of a
modified TIE2 promoter containing LacO transcriptional regulation sites
(positions 2117, 225 and +67), Cx40 transgene (Cx40Tg), an internal
ribosomal entry sequence (IRES), EGFP, PolyA tail and TIE2 Enhancer
element. Proteins expressed from this construct are translated
separately due to the presence of the IRES sequence. (B) When bred
with LacIR mice, expression of the Cx40Tg should be repressed due to
binding of the LacIR protein (pink) to the LacO sites incorporated into
the TIE2 promoter. (C) In the presence of IPTG (blue circles) LacIR
undergoes a conformational change lessening its affinity for the LacO
sites and transcription can proceed.
doi:10.1371/journal.pone.0095980.g001
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Generation of transgenic mice
TIE2LacO-Cx40Tg-EGFP mice. The final construct was
digested with Pvu I and BssH II and gel purified to remove vector
sequence prior to use in the generation of transgenic mice.
Transgenic C57BL/6 mice were produced by pronuclear injection
of the 19 kb construct (TASQ, University of Queensland,
Australia). Transgenic founders were identified by PCR.
Selection of transgenic lines. Copy number of the trans-
gene was determined in founder mice (N0) and offspring of the
next three generations (N1-N3), using quantitative real time PCR
(qPCR) for the reporter gene EGFP relative to a known single
copy gene, transferrin. EGFP expression was quantified using
Western Blotting. Mice with different transgene copy numbers
were bred as separate colonies from N1, N2 and N3 generations to
confirm segregation and stabilisation of different copy numbers.
LacIR mice. Mice from this strain were developed to be
homozygous for a transgene that expresses the LacIR inhibitor
protein under control of the ubiquitous b-actin promoter [8]. The
heterozygous LacIR strain was a generous gift from Professor Heidi
Scrable, University of Virginia, Charlottesville, Virginia, USA.
Homozygous mice were identified from heterozygous matings
using qPCR of genomic DNA for LacIR. Homozygosity was
determined by test breeding with wildtype mice and by
quantifying expression of LacIR protein in offspring by Western
Blotting.
TIE2LacO-Cx40Tg-EGFP/LacIR mice were generated by crossing
the TIE2LacO-Cx40Tg-EGFP mice with homozygous LacIR mice
(Figure 1B) [8].
Quantitative Real Time PCR (qPCR)
qPCR to determine EGFP Transgene Copy
Number. Two standard reference curves were generated. The
first was a series of 2-fold dilutions of wildtype mouse genomic
DNA, from 8 ng/ml to 0.25 ng/ml, in T10E0.1 containing 4 ng/ml
tRNA (Sigma) as carrier. The mouse transferrin gene was used as a
single copy reference [13] using the primers detailed in Table 1.
The second standard used purified plasmid DNA containing the
entire TIE2LacO-Cx40-EGFP transgene construct. Serial 10-fold
dilutions of the plasmid DNA were made from 2.561022 ng/ml to
2.561027 ng/ml, again using T10E0.1 containing 4 ng/ml tRNA as
carrier. The primers for EGFP are detailed in Table 1.
Genomic DNA from each mouse to be tested was quantified
using the high sensitivity QUBIT assay (Invitrogen) and diluted to
4 ng/ml in T10E0.1. Each experimental sample was prepared in
triplicate and amplified for EGFP and transferrin. Each qPCR run
contained the 6 standard reference samples for transferrin and for
EGFP, 15 test samples and a negative control without DNA, all in
triplicate.
Each qPCR reaction contained 10ml of 2x Sensimix+SYBR (No
ROX) master mix (Bioline), 5mM forward and reverse primer, 5ml
of DNA sample and water to a total volume of 20ml. PCR was
performed in a Corbett Research Rotor-Gene RG-3000 Real
Time Analyser with cycling conditions as follows: 95uC for
10 minutes, followed by 40 cycles of 95uC for 10 s, annealing
temp (see Table 1) for 20 s and 72uC for 20 s. Melt curves were
performed after each run to ensure the amplification of a single
product. The data was analysed using the Rotagene 6.0 software
and copy number calculated from the standard curves.
qPCR to determine LacI Zygosity. Genomic DNA from a
mouse known to be heterozygous for the LacIR transgene was
quantified using the QUBIT (Invitrogen) and diluted to 16 ng/ml
in T10E0.1 containing 4 ng/ml tRNA as carrier. A standard curve
ranging from 8 ng/ml to 0.25 ng/ml genomic DNA was prepared
by 2-fold serial dilutions in triplicate in T10E0.1 containing 4 ng/ml
tRNA as carrier diluent. Transferrin was again used as a single
copy gene reference [13].
DNA samples from test mice were prepared as above in
triplicate and amplified with the LacIR and transferrin primers as
detailed in Table 1. The ratio of LacIR to transferrin for the known
heterozygote was normalised to 1.00. Test samples were normal-
ised accordingly and the ratio used as a predictor of zygosity.
Western blot detection of EGFP
Mice were anaesthetised with isoflurane, decapitated, and
mesenteric arteries were removed and stripped of fat in ice cold
phosphate buffered saline (PBS) prior to being snap frozen in
liquid nitrogen. Frozen tissues were pulverised under liquid
nitrogen in the presence of 100ml of frozen extraction buffer
(37 mM TRIS, 0.5% lithium dodecyl sulphate, 2.5% glycerol,
0.13 mM EDTA, 0.06 mM SERVA blue G250, 0.04 mM phenol
red, 50 mM DTT, 1X cOmplete mini Protease Inhibitor Cocktail
[Roche], pH 8.5). Frozen extracts were allowed to thaw on ice and
the resulting liquid extract was transferred to a plastic sample tube.
The remaining sample was washed from the mortar using a
further 50ml of sample buffer and recovered into the same plastic
sample tube. Extracts were then heated at 70uC for 5 min,
vortexed and heated for a further 5 min before being stored at 2
20uC until analysis.
Proteins present in tissue extracts were resolved by SDS
denaturing electrophoresis on NuPAGE 4–12% BIS-TRIS gradi-
ent gels using NuPAGE MES buffer according to the manufac-
turer’s recommended protocols (Invitrogen). Proteins were trans-
ferred onto PVDF membranes at 180 mA in NuPAGE transfer
buffer for 4 h at RT.
Membranes were recovered, and air dried at room temperature
for 1 h. Membranes were rehydrated with 100% methanol,
followed by 50% methanol in PBS for 5 minutes each.
Table 1. Primer sequences and conditions for quantitative PCR.
Primer Sequence Annealing Temp Amplicon size
Transferrin F 59-ATCCCAGTGACTACAACGGTTCCA-39 63uC 189bp
Transferrin R 59-AGACCACAACATGGTTTGGAGCTT-39
EGFP F 59-TCTATATCATGGCCGACAAGCAGA-39 65uC 165bp
EGFP R 59- ACTGGGTGCTCAGGTAGTGGTTGT 39
LacIR F 59-GGTGTCTCTTATCAGACTGTTTCCA-39 67uC 206bp
LacIR R 59-GCTGCCACAATTTGAGATGGTGCA-39
doi:10.1371/journal.pone.0095980.t001
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Membranes were then blocked with 2% BSA in PBS for 1 hour at
RT. Membranes were washed 6 times with PBST (PBS, 0.05%
Tween-20) for 10 minutes each. Primary antibody: mouse anti-
GFP monoclonal IgG1 (kindly supplied by Jan Elliot, Research
School of Biology, Australian National University), mouse anti-
LacI (Millipore), mouse anti-a-smooth muscle actin (aSMA,
Sigma), rabbit anti-vonWillebrand Factor (vWBF, Dako); was
applied to the blot (1:1000 anti-GFP; 1:2000 anti-LacI; 1:10000
anti-aSMA; 1:2000 anti-vWBF; diluted in 2% BSA in PBST) for
16 hrs at 4uC. Membranes were washed 6 times with PBST for
10 minutes. Secondary antibody (goat anti-mouse HRP conjugate,
Millipore, or goat anti-rabbit HRP conjugate, Sigma) was applied
to the blot (1:2000 for EGFP; 1:2000 for LacI; 1:10000 for aSMA,
1:2000 for vWBF; diluted in 2% BSA in PBST) for 2 h at RT.
Membranes were washed 6 times in PBST, followed by 1 wash in
PBS, each for 10 minutes. The signal was developed using
Immobilon Western chemiluminescent substrate according to the
manufacturer’s recommended protocol (Millipore). Image record-
ing was performed on a LAS1000 system (Fujifilm). The EGFP +
ve control was from a mouse expressing an EGFP tagged with a
nuclear localization signal and the EGFP protein therefore has a
slightly higher molecular weight than standard EGFP.
Band signal intensity was measured using ImageQuant TL
Software Version 7.0 (GE Healthcare). EGFP and LacI quanti-
fication was normalised to either the smooth muscle marker, a-
actin, or the endothelial marker, vWBF expression, respectively.
Immunohistochemical detection of EGFP
Mice were anaesthetised with isoflurane, decapitated and
kidneys, mesenteric and basilar arteries removed. Kidneys were
placed in ice cold PBS and the capsules were removed and the
kidneys were cut into 3–4 mm transverse slices. Mesenteric
arteries were placed into ice-cold PBS and surrounding fat
removed. All tissues were immersion fixed in 2% paraformalde-
hyde and 0.01% sodium nitrite (100 mM sodium phosphate
buffer) for 10 min, then cryprotected in 30% sucrose in PBS
overnight. Tissues were finally embedded in Tissue Tek O.C.T
(Sakura Fintek USA, Torrance, CA), frozen and cut into 30mm
sections using a cryostat.
Cremaster arterioles. Cremaster muscles were removed
from mice which were anaesthetised (1 mg/kg medetomidine,
10 mg/kg midazolam, and 0.1 mg/kg Fentanyl, i.p.) and contin-
uously perfused with anaesthetic (0.2 mg/h medetomidine,
0.2 mg/h midazolam, 0.002 mg/h fentanyl) via a jugular vein
cannula during the procedure. Isolated cremaster muscles were
fixed in 2% paraformaldehyde and cryosections prepared as
above. Mice were euthanised by cervical dislocation whilst still
deeply anaesthetised.
Tissue sections were preincubated for 30 min in PBS containing
2% bovine serum albumin, 0.2% Triton-X100, and 0.04% sodium
azide before being incubated at room temperature for 24 h with
rabbit anti-GFP antibodies (Invitrogen) diluted 1:1000 in the pre-
incubation solution. Sections were washed three times in PBS and
incubated for 2 h with Alexa-488 conjugated donkey anti-rabbit
antibodies (Invitrogen) diluted 1:400 with PBS containing 0.02%
Triton-X100. Sections were then incubated in PBS containing
0.01% pontamine sky blue for 3 min to shift the green
autofluorescence of the vascular internal elastic lamina to longer
wavelengths. Finally, sections were washed three times with PBS
before being mounted in buffered glycerol.
Confocal microscopy and image analysis
Image series of all stained tissues were taken with a Leica SP2
confocal scanning microscope. For time course studies, the same
acquisition settings were used to collect images to enable the
degree of staining to be compared at different time points. For
quantification of EGFP staining in the kidney, image series were
taken using a 20x lens with z plane increments of 1.5 mm. For each
image series, an average projection image was generated and three
such composite images from each animal were used to quantify
EGFP expression.
Quantification of EGFP staining. For each image, areas of
endothelial tissue were identified by their location on the inner
surface of the auto-fluorescence generated by the internal elastic
lamina (red). Using the polygon selection and histogram functions
in ImageJ (National Centre for Biotechnology Information), the
intensity of EGFP staining (green) was calculated. For each image
the EGFP signal within several non-endothelial tissues such as
tubules and vascular smooth muscle were also calculated. EGFP
expression was quantified as signal to noise ratio minus one using
the equation, (Endothelial Cell Intensity/Background Intensity)-1.
IPTG Treatment of TIE2LacO-Cx40Tg-EGFP/LacIR mice
The TIE2LacO-Cx40Tg-EGFP/LacIR mice were given IPTG
(Inalco, USA; Figure 1C) with doses ranging from 10 to 80 mM in
the drinking water for periods of 2 to 14 days. Sucrose (2%) was
added to encourage consumption at higher concentrations (40 and
80 mM); an approach commonly used to reduce the bitter taste of
Doxycycline [14]. Controls received 2% sucrose in water. Doses as
high as 10% sucrose have previously been reported to have no
effect on blood glucose, insulin or adiponectin levels, nor on
glucose tolerance [15]. Following treatment, mice were euthanised
and analysed for EGFP expression by Western Blotting or
immunohistochemistry.
Statistical Analysis
Data are presented as means 6 SEM where n represents the
number of mice. Statistical significance was determined by one-
way ANOVA with Bonferonni post-hoc test for multiple
comparisons, with P,0.05 considered significant.
Results
Transgene Inheritance is unstable in early generations
Transgene copy number was monitored in the T152ATg mouse
strain over the first generation (N1) and found to vary from 4 to 22
copies. Subsequent breeding to C57BL/6 wildtype mice showed
that this variability continued into the next two generations before
stabilizing with breeder selection at 12 copies. The production of
equal numbers of transgenic to wildtype offspring in each
generation was consistent with a single integration site, suggesting
some instability of the multiple transgene copies at the one
insertion site.
The T202STg strain was bred for 6 generations to wildtype
mice and copy number stabilized at 360 copies. At this stage, equal
numbers of transgenic to wildtype offspring were still found in
each generation, again consistent with a single integration site.
Insertion of LacO sites in the TIE2 promoter does not
compromise endothelial specificity
In order to determine the cellular distribution of the transgene
expression, we conducted immunohistochemical studies in the
vasculature using antibodies against the reporter EGFP. We did
not study Cx40 expression as antibodies against Cx40 were unable
to discriminate the Cx40 transgene from wildtype Cx40, which is
highly expressed in the vascular endothelium [16].
No staining was detected in arteries or arterioles of wildtype
mice (Figure 2A, C, E, G, I). In contrast, EGFP was detected
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uniformly in the endothelium of arteries and arterioles of several
different systemic and cerebral circulations of transgenic mice,
while staining was absent from the arterial smooth muscle or
adventitia. Vessels studied included mesenteric (Figure 2B) and
basilar (Figure 2D) arteries, as well as cremaster muscle arterioles
(Figure 2F), renal arteries, arterioles and glomerular capillaries
(Figure 2H, J).
Homozygous LacIR mice can be reliably identified by
qPCR
Since repression of transgene expression required interbreeding
of transgenic mouse strains (TIE2LacO-Cx40Tg-EGFP mice and
LacIR mice), we developed a homozygous LacIR strain to ensure
that all offspring in each generation would express LacIR and 50%
of these mice would also be transgenic for Cx40. Our first aim was
therefore to develop a rapid assay to detect homozygous offspring
from heterozygous matings and validate the assay by test breeding
and Western blot protein assay.
Offspring from matings of heterozygous LacIR mice were used to
provide samples for qPCR using primers and standard curves for
both LacIR and the single copy gene, transferrin. LacIR/transferrin
values were calculated for each mouse and zygosity values
obtained by normalizing these values to that of a known
heterozygote LacIR mouse, whose zygosity was defined as 1.0.
When data from 136 offspring were plotted, a bimodal distribution
was found, consistent with a large heterozygous and smaller
homozygous population (Figure 3A). From this distribution we
defined a homozygote as any animal with a zygosity value $1.5.
Figure 3B shows that interbreeding of 4 heterozygous mice,
defined by zygosity values,1.5, produced a total of 42 offspring of
which 11 were wildtype (zygosity = 0), 21 were heterozygotes
(zygosity ,1.5) and 10 were homozygotes (zygosity $1.5). These
numbers accord well with Mendelian segregation which would
predict a ratio of 10.5 wildtype: 21 heterozygotes: 10.5 homozy-
gotes from a heterozygous mating producing the same number of
offspring.
Subsequent breeding of 5 mice with zygosity values $1.5 (1.5,
1.8, 1.8 1.9, 2.1) to wildtype mice, each produced 100% LacIR
transgenic mice (41 offspring), with zygosity values ,1.5
(Figure 3B), as expected for a homozygous/wildtype mating.
Western blotting showed that mesenteric arterial samples taken
from mice with zygosity values $1.5 showed higher LacIR
expression than samples from mice with zygosity values ,1.5
(Figure 3C). Quantification of LacIR bands, relative to the
endothelial marker vWBF, showed that LacIR expression was 2-
fold higher in samples from mice with zygosity values of $1.5
compared to those from mice with zygosity values of ,1.5
(Figure 3D), consistent with assignation of homozygosity and
heterozygosity to zygosity values of $1.5 and ,1.5, respectively.
LacIR protein significantly reduces transgene expression
in vivo
When TIE2LacO-Cx40Tg-EGFP mice were interbred with
LacIR mice, EGFP expression in primary mesenteric arteries of
both transgenic strains, T152ALacIR and T202SLacIR, was
reduced significantly by 71% and 100%, respectively (Western
blots; T152ALacIR: Figure 4A, C; T202SLacIR: Figure 4B, D).
Immunohistochemical analyses of kidney sections of T152ALa-
cIR and T202SLacIR mice showed that endothelial specific
expression of EGFP was similarly reduced by 65% and 91%,
compared to T152ATg and T202STg mice, respectively
(T152ALacIR: Figure 5A, C, E, K; T202SLacIR: Figure 5B, D, F,
L).
Expression of LacIR protein was not significantly different
between mesenteric arterial samples taken from T152ALacIR and
Figure 2. Maintenance of endothelial tissue specificity of the
TIE2 promoter when modified with LacO sites. EGFP was
expressed in the endothelial cells (EC) of primary mesenteric arteries
and basilar arteries of transgenic mice (Cx40Tg; B, D), as well as in
cremaster muscle arterioles (F) and kidney arteries, arterioles and
glomerular capillaries (H, J). EGFP was not detectable in arterial smooth
muscle (SMC) or in renal tubules. No EGFP was detected in comparable
vessels of wildtype mice (A, C, E, G, I). IEL represents the internal elastic
lamina; aff art, afferent arteriole. Examples from Cx40T152ATg (B, J) and
Cx40T202STg mice (D, F, H).
doi:10.1371/journal.pone.0095980.g002
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T202SLacIR mice, when quantified relative to the smooth muscle
marker, a-actin (T152ALacIR mice: 3.260.5 LacIR/actin, n= 9
mice; T202SLacIR mice: 3.160.3 LacIR/actin, n= 6 mice).
Together, these data show that the LacIR protein is expressed to
the same extent in the 2 transgenic mouse strains and can reliably
and significantly reduce transgene expression in vivo.
Figure 3. Detection of LacIR homozygosity using quantitative PCR. (A) Binning of zygosity values from heterozygous matings demonstrates
two populations indicative of heterozygotes and homozygotes. (B) Interbreeding of predicted heterozygotes produces wildtype, heterozygote and
homozygote populations in Mendelian ratios. (C) LacIR expression in predicted homozygotes (zygosity $1.5) is greater than in predicted
heterozygotes (zygosity ,1.5). Representative blots and group data for 3 heterozygote and 5 homozygote samples. WT wildtype. *P,0.05 denotes
significant difference.
doi:10.1371/journal.pone.0095980.g003
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De-repression of transgene expression can be achieved
by administration of IPTG
Preliminary experiments testing low concentrations of IPTG (10
and 20 mM) produced variable induction of transgene expression
(data not shown). To encourage consumption of higher concen-
trations of IPTG (40 and 80 mM), 2% sucrose was added to the
drinking water. Measurement of blood glucose before and after
2% sucrose treatment confirmed that blood glucose levels were not
altered by sucrose addition for 7 or 14 days (Before: 7.860.4 mM,
n=8 mice; 7 day sucrose: 8.160.3 mM, n= 8 mice; 14 day
sucrose: 6.860.3 mM, n= 8 mice). Addition of either 40 mM or
80 mM IPTG with 2% sucrose to the drinking water did also not
Figure 4. Control of EGFP expression by LacIR and IPTG: Western blotting. Western blots of mesenteric arterial samples demonstrate
repression of EGFP expression by breeding of Cx40 (T152ATg and T202STg) transgenic mice with LacIR mice (T152ALacIR mice: A, C; T202SLacIR mice:
B, D). De-repression of EGFP by IPTG is found in T152ALacIRmice after 14 days (A, C), but not in T202SLacIR mice (B, D). (C). Group data (left to right):
n = 6, 9, 11, 5, 5, 8, 7 mice. (D). Group data (left to right): n = 4, 6, 2, 4 mice. WT, wildtype. Positive control for EGFP is from a mouse expressing EGFP
tagged with a nuclear localisation signal and therefore has a slightly higher molecular weight. *P,0.05 denotes significant difference; ANOVA
followed by Bonferonni tests for multiple groups.
doi:10.1371/journal.pone.0095980.g004
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significantly alter the average volume of water drunk by each
mouse per day (2% sucrose in water: 4.560.6 ml, n= 6 mice;
40 mM IPTG+ sucrose: 4.660.5 ml, n= 9 mice; 80 mM IPTG+
sucrose: 5.160.5 ml, n= 12 mice). Mice given IPTG did not show
any abnormalities in regard to coat appearance, hydration,
grooming, general activity, or food and water consumption.
Administration of 40 mM IPTG to T152ALacIRmice over a
period of 14 days led to a gradual increase in transgene expression
in mesenteric arteries, as measured by Western blotting (Figure 4A,
C). After 14 days of IPTG treatment, transgene expression was
significantly higher than in untreated T152ALacIR mice and had
recovered to 70% of that in T152A transgenic mice (Figure 4C).
When assayed immunohistochemically in kidney sections, endo-
thelial transgene expression similarly increased over 14 days, with
expression after 14 days’ treatment significantly increased com-
pared to untreated T152ALacIRmice and recovery to 60% of that
in T152A transgenic mice (Figure 5E, G, K). Doubling the
concentration of IPTG to 80 mM did not produce any further
increase in transgene expression after 14 days’ treatment (Western
blot: Figure 4A, C; Immunohistochemistry: Figure 5I, K).
In contrast, administration of 40 mM or 80 mM IPTG to
T202SLacIR mice for 14 days failed to significantly induce
transgene expression, assayed either by Western blotting
(Figure 4B, D) or immunohistochemistry (Figure 5F, H, J, L).
Moreover, the minimally increased transgene expression that was
seen in T202SLacIR mice, not only varied between animals, but
also amongst vessels in the same animal (data not shown).
Discussion
The present study has tested a modified bacterial lac operon
system, developed originally by Scrable and colleagues [6–8], to
reversibly control gene expression in the vasculature in vivo. We
show that this system can be used to reliably repress gene
expression selectively in the vascular endothelium, through the use
of the modified endothelial specific promoter TIE2 [11]. This
ability thus enables the unambiguous attribution of phenotype to
the transgene, eliminating any influence of the site of transgene
integration into the genome. Our data also show that transgene
expression can be de-repressed rapidly by the innocuous inducer,
IPTG, in one transgenic line.
Modification of the promoter with LacO sites
Modification of the TIE2 promoter with three LacO sites and
generation of transgenic mice did not alter the tissue specificity of
this promoter in directing expression of the EGFP reporter. The
uniform, endothelial cell specific protein expression for EGFP
found here in several different arteries and arterioles of adult mice
was entirely consistent with the expression pattern reported in the
literature for the TIE2 promoter with its enhancer element [11].
These data thus extend the findings of Scrable and colleagues in
the use of this system, from more generalised promoters [6–8] to a
vascular specific promoter, to show that tissue specificity is not
compromised by the addition of three LacO sequences spanning
the transcription start site. However, although our data suggests
that a large number of different promoters might be amenable to
such a modification, their specificity will have to be carefully
verified after introduction of the LacO sites.
In contrast to the uniform transgene expression that we found
with the TIE2 promoter, Grespi and colleagues reported variable
expression amongst different immune cell populations and
different tissues when directed by the Vav-gene promoter [9].
While some of this variegation may have resulted from the
persistence of multiple transgene insertion sites in F2 progeny, it
should also be noted that the Vav-gene construct contained viral
sequences, both in the intron, as well as the PolyA signal. Mosaic
expression might therefore be expected as these sequences would
be subjected to silencing through methylation. It is possible that
our constructs avoided such modifications since they consisted
entirely of mammalian DNA sequences.
Silencing of transgene expression in vivo with LacIR
Expression of EGFP in both of the transgenic mouse lines
established in this study was significantly repressed by interbreed-
Figure 5. Control of EGFP expression by LacIR and IPTG:
Immunohistochemistry. Immunohistochemical staining for EGFP
demonstrates endothelial (EC) staining in T152A (C) and T202S
transgenic mice (D) but not in wildtype (A) or LacIR (B) mice.
Interbreeding of transgenic mice with LacIR mice led to a significant
reduction in EGFP staining in both transgenic strains (E, F). De-
repression of EGFP by IPTG is found in T152ALacIR mice after 14 days (I,
K), but not in T202SLacIR mice (J, L). (K) Group data (left to right): n = 7,
12, 7, 4, 5, 7, 5 mice. (L) Group data (left to right): n = 6, 8, 4, 8, 4 mice.
*P,0.05 denotes significant difference; ANOVA followed by Bonferonni
tests for multiple groups.
doi:10.1371/journal.pone.0095980.g005
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ing with a mouse line ubiquitously expressing the repressor protein
LacIR. In T202SLacIR mice, expression was fully repressed, while in
T152ALacIR mice, transgene expression was repressed by 70%.
Our current studies of cardiovascular function have confirmed
that repression in both transgenic lines is extended in a similar
manner to the physiological phenotypes resulting from expression
of the mutant endothelial Cx40 transgenes. We see altered blood
pressure which is significantly reversed by LacIR in both strains of
mice (data under Journal submission). Such repression of
transgene expression by LacIR in vivo enables the unequivocal
attribution of phenotypes to transgenes, thus eliminating artefacts
due to the site of integration into the genome. The development
and validation in this study of a simple and reliable method for
identifying homozygous transgenic LacIR mice using qPCR,
further facilitates the use of this system by increasing the
probability of production of the requisite doubly transgenic mice.
De-repression of transgene expression in vivo using IPTG
Of surprise was the finding that the ability of IPTG to reinstate
transgene expression varied between the 2 transgenic mouse
strains. Thus, in T152ALacIR mice, daily administration of IPTG
led to a rapid reinstatement of transgene expression to 70% of full
activity, while in the T202SLacIR mice, transgene expression was
variable and inconsistent. A correlation thus existed between the
extent of repression by the repressor protein LacIR and the ability
of IPTG to reinstate transgene expression. The variation in
transgene regulation was unexpected, as the T152ALacIR and
T202SLacIR transgenic mice were produced using the same
promoter construct with the three LacO sites located in the same
positions. Indeed, the only differences in the constructs were the
two, single nucleotide changes within the connexin gene sequence:
a change unlikely to affect the ability of a promoter to regulate
transgene expression.
The variability in de-repression in vivo of the T152A and T202S
transgenes suggests that the activity of the TIE2LacO promoter
may have been affected by the site of transgene integration.
However, this is unlikely since the use of the TIE2 enhancer
sequences, in conjunction with the TIE2 promoter, has been
shown to ensure consistent and endothelial cell specific activity
[11,17,18], as we confirm here. Differences in the availability of
the LacIR protein to the LacO sequences also seem unlikely, since
LacIR protein expression was identical in mesenteric arteries of the
T152ALacIR and T202SLacIR transgenic mice. Finally, variability
in access and activity of IPTG in the target endothelial cells is
unlikely, as IPTG was replenished daily over the 14 day exposure
period and previous studies have shown that IPTG can remain
active after crossing both the blood-brain barrier and the placenta
[8].
In spite of the similarity in the 2 transgenic constructs, a major
difference that did exist between the T152A and T202S transgenic
mouse strains was transgene copy number. Interestingly, the high
copy number strain (T202S) was the one in which transgene
expression could be completely repressed by LacIR but not de-
repressed by IPTG. Since it is known that high copy number
transgenic mice have more highly compacted heterochromatin
(see for e.g.[19,20]) and that the LacIR protein forms tetramers
between a number of different LacO sites [21], it is possible that
the numerous T202S transgene copies are more tightly packed
and more compressed by LacIR, than the less numerous T152A
transgene copies. It would then follow that this conformation could
not be de-repressed by IPTG. Indeed if correct, this phenomenon
could be an advantage for future studies where different founders
could be chosen based on copy number, allowing a gene to be
totally repressed in high copy number founders, and de-repressed
in low copy number founders. However, more founder lines with
varying copy numbers are required to confirm this association.
Conclusions
Using a vascular cell type specific promoter, we have shown that
the repressor protein LacIR of the bacterial lac operon system, when
modified for use in mammalian cells, can reliably repress
transgene expression in vivo, thus enabling the attribution of
phenotype to the transgene, rather than to the insertion site.
Moreover, the introduction into the promoter of LacO sites does
not compromise tissue specificity, making this an attractive system
to validate transgenic phenotypes. While rapid de-repression of
transgene expression by the innocuous inducer, IPTG, has been
reported previously for both the tyrosinase and Huntington
promoters [6–8], in the present study this only occurred reliably
in one of our transgenic lines, even though the constructs were
essentially identical. Should studies in which de-repression be of
interest, for example, to study gene expression in adulthood
without developmental complications, the development of several
founders may be required to identify a line in which this feature of
the system is possible. In this connection, the inverse correlation
between the degree of repression by LacIR and the ability of IPTG
to reinstate expression, a feature also described in a previous study
[9], may be a useful index to rapidly identify transgenic lines in
which de-repression by IPTG will be possible.
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